GAITHERSBURG, MD, March 11, 2019 -- PRNewswire
Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that the Company's management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts.
Patrick Lu, PhD, President and Chief Executive Officer, will share an overview of Sirnaomics' differentiated RNAi technology platform, which leverages a proprietary polypeptide nanoparticle (PNP) drug delivery system, and the Company's pipeline of RNAi therapeutics spanning oncology and anti-fibrosis indications at the following presentations.
Presentation: Chairperson's Remarks Date & Time: March 26, 10:45 am ET
Presentation Title: Novel siRNA Therapeutics for Immune Oncology Therapeutics Presentation Track: Oligonucleotide Discovery and Delivery Date & Time: March 26, 2 pm ET
Presentation Title: Can We Push for siRNA Cancer Therapeutics Similar to Experiences with mAbs? Date & Time: March 27, 8 am ET
Also, Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics, will chair a short course, "Examining The Safety and Toxicity of Nucleic Acid Therapeutics", on Monday, March 25 starting at 6:50 pm ET. He will also participate in a panel discussion, "Bridging the Gap between Discovery, Development and Compliance", on Tuesday, March 26 at 9:15 am ET.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.
Sirnaomics, Inc. Michael Molyneaux MD MBA Chief Medical Officer firstname.lastname@example.org
ICR Healthcare Investors: Stephanie Carrington Tel: +1 646 277 1282 Email: Stephanie.Carrington@icrinc.com
Media: James Heins Tel: +1 203 682 8251 Email: James.Heins@icrinc.com
SOURCE Sirnaomics, Inc.